Visceral leishmaniasis: an endemic disease with global impact

Abstract number: S322-S324

Alvar J., Sundar S., Gangneux J.-P.

Visceral Leishmaniasis (VL) is the second most common protozoal infection after malaria worldwide and affects approximately 2 million people per year predominantly in sub-Saharan Africa and the Indian subcontinent. Co-infection with HIV has become a major public health threat in endemic areas. Therapy has been traditionally prolonged, requiring affected individuals to remain in hospital or under medical supervision for several weeks. Providing access to medicines is problematic given the worst-affected regions tend to be poverty-stricken, geographically remote or affected by conflict which makes it difficult for aid agencies to provide the treatment programmes required to address the burden of care.

Non-governmental agencies such as the WHO, DNDi and MSF in collaboration with VL specialists have been working to provide treatment programmes as well as conduct clinical research with newer or better-tolerated agents in order to establish shorter treatment times, optimise therapeutic strategies and assess the cost-effectiveness of different approaches.

This symposium will address the burden of disease and the steps the NGO's have been taking to manage VL as well as review the literature on VL to discuss optimum therapy. This disease is also endemic in parts of Europe and infects mostly HIV-infected adults and more rarely patients with other T cell immune deficiencies such as solid organ transplant patients or those receiving anti-TNF-a antibodies, although rare. The symposium will also address the issue of VL as a differential diagnosis in European patients and whether data from studies in India and Africa are relevant in Europe or on other continents.

Session Details

Date: 07/05/2011
Time: 00:00-00:00
Session name: Abstracts of 21st ECCMID / 27th ICC
Location: Milan, Italy, 7 - 10 May 2011
Presentation type:
Back to top